Ana Arance

35.6k total citations · 7 hit papers
182 papers, 8.5k citations indexed

About

Ana Arance is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ana Arance has authored 182 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Oncology, 117 papers in Molecular Biology and 34 papers in Immunology. Recurrent topics in Ana Arance's work include Melanoma and MAPK Pathways (107 papers), Cancer Immunotherapy and Biomarkers (93 papers) and CAR-T cell therapy research (80 papers). Ana Arance is often cited by papers focused on Melanoma and MAPK Pathways (107 papers), Cancer Immunotherapy and Biomarkers (93 papers) and CAR-T cell therapy research (80 papers). Ana Arance collaborates with scholars based in Spain, United States and France. Ana Arance's co-authors include Caroline Robert, Jean‐Jacques Grob, Georgina V. Long, James Larkin, Omid Hamid, Matteo S. Carlino, Reinhard Dummer, Laurent Mortier, Jacob Schachter and Paul Lorigan and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ana Arance

165 papers receiving 8.4k citations

Hit Papers

Pembrolizumab versus ipilimumab for advanced melanoma: fi... 2015 2026 2018 2022 2017 2019 2015 2019 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
    2017 898 citations Jacob Schachter, Antoni Ribas et al. profile →
  2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
  3. Clinical implications of the intrinsic molecular subtypes of breast cancer
    2015 751 citations Aleix Prat, Estela Pineda et al. profile →
  4. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    2019 703 citations Georgina V. Long, Reinhard Dummer et al. profile →
  5. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
    2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
  6. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
    2017 482 citations Philippe Saïag, Caroline Robert et al. profile →
  7. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
    2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ana Arance Spain 35 6.3k 4.1k 2.1k 1.5k 1.0k 182 8.5k
Helen Gogas Greece 49 6.5k 1.0× 3.8k 0.9× 2.2k 1.1× 1.1k 0.7× 1.1k 1.1× 330 9.2k
René González United States 48 6.6k 1.1× 4.4k 1.1× 2.6k 1.3× 1.2k 0.8× 729 0.7× 189 9.2k
Paola Queirolo Italy 44 5.3k 0.9× 3.0k 0.7× 2.5k 1.2× 951 0.6× 662 0.6× 233 7.3k
James S. Wilmott Australia 36 4.4k 0.7× 2.8k 0.7× 2.4k 1.1× 1.0k 0.7× 798 0.8× 139 6.4k
Kevin B. Kim United States 38 5.1k 0.8× 5.4k 1.3× 1.0k 0.5× 1.5k 1.0× 970 0.9× 116 8.2k
Matteo S. Carlino Australia 51 9.6k 1.5× 4.7k 1.1× 3.7k 1.8× 2.0k 1.3× 1.5k 1.4× 303 12.5k
Vanna Chiarion‐Sileni Italy 51 7.3k 1.2× 4.1k 1.0× 3.1k 1.5× 2.2k 1.4× 551 0.5× 244 10.4k
Alexander M. Menzies Australia 55 9.8k 1.6× 5.1k 1.2× 3.2k 1.5× 2.5k 1.6× 1.2k 1.2× 330 12.6k
Jacob Schachter Israel 47 6.5k 1.0× 3.0k 0.7× 3.0k 1.4× 857 0.6× 748 0.7× 189 8.4k
Lauren E. Haydu Australia 37 5.1k 0.8× 3.8k 0.9× 1.2k 0.6× 774 0.5× 686 0.7× 124 6.7k

Countries citing papers authored by Ana Arance

Since Specialization
Citations

This map shows the geographic impact of Ana Arance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Arance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Arance more than expected).

Fields of papers citing papers by Ana Arance

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Arance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Arance. The network helps show where Ana Arance may publish in the future.

Co-authorship network of co-authors of Ana Arance

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Arance. A scholar is included among the top collaborators of Ana Arance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Arance. Ana Arance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arance, Ana, P.A. Ascierto, Simran Sandhu, et al.. (2025). LBA53 IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: Primary phase III results (IOB-013/KN-D18). Annals of Oncology. 36. S1597–S1598.
2.
Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2025). 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma. Annals of Oncology. 36. S887–S888.
3.
González‐Ortiz, Sofía, Andrés Perissinotti, Ibán Aldecoa, et al.. (2025). Assessing brain metastasis response to immunotherapy: a pictorial review of atypical responses and intracranial adverse events. Insights into Imaging. 16(1). 258–258.
4.
Lipson, Evan J., F. Stephen Hodi, Hussein Tawbi, et al.. (2025). Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. European Journal of Cancer. 225. 115547–115547. 1 indexed citations
5.
Arance, Ana, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, et al.. (2025). Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Annals of Oncology. 36(12). 1535–1546.
6.
Schadendorf, Dirk, Caroline Robert, Ana Arance, et al.. (2024). COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European Journal of Cancer. 204. 114073–114073. 22 indexed citations
7.
Robert, Caroline, Caroline Dutriaux, Felix Boakye Oppong, et al.. (2024). Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).. Journal of Clinical Oncology. 42(17_suppl). LBA9503–LBA9503. 3 indexed citations
8.
Melero, Ignacio, Judy S. Wang, Martin Gutierrez, et al.. (2024). Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.. Journal of Clinical Oncology. 42(16_suppl). 2588–2588. 1 indexed citations
9.
Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2024). Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. Journal of Clinical Oncology. 43(13). 1546–1552. 24 indexed citations
10.
Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2023). Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.. Journal of Clinical Oncology. 41(16_suppl). 9502–9502. 7 indexed citations
11.
12.
Pascual, Tomás, Blanca González‐Farré, Fara Brasó‐Maristany, et al.. (2023). 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types. Annals of Oncology. 34. S1153–S1154. 1 indexed citations
13.
Haydon, Andrew, Dirk Schadendorf, Reinhard Dummer, et al.. (2023). 602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Annals of Oncology. 34. S1707–S1708. 2 indexed citations
14.
Ascierto, Paolo A., Reinhard Dummer, Helen Gogas, et al.. (2023). Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology. 41(29). 4621–4631. 15 indexed citations
15.
Robert, Caroline, Matteo S. Carlino, Catriona M. McNeil, et al.. (2023). Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology. 41(24). 3998–4003. 63 indexed citations
16.
Serra-Bellver, Patricio, Judith M. Versluis, Cong Zhou, et al.. (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European Journal of Cancer. 176. 121–132. 14 indexed citations
17.
Hamid, Omid, Caroline Robert, Adil Daud, et al.. (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer. 157. 391–402. 19 indexed citations
18.
Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550. 277 indexed citations
19.
Prat, Aleix, Huihui Fan, Aranzazu Fernández-Martínez, et al.. (2015). Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine. 13(1). 303–303. 112 indexed citations
20.
Yagüe, Ernesto, Ana Arance, Michael J. O’Hare, et al.. (2007). Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process. Cancer Research. 67(3). 1130–1137. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helen Gogas Breakdown of academic impact, for papers by René González Breakdown of academic impact, for papers by Paola Queirolo Breakdown of academic impact, for papers by James S. Wilmott Breakdown of academic impact, for papers by Kevin B. Kim Breakdown of academic impact, for papers by Matteo S. Carlino Breakdown of academic impact, for papers by Vanna Chiarion‐Sileni Breakdown of academic impact, for papers by Alexander M. Menzies Breakdown of academic impact, for papers by Jacob Schachter Breakdown of academic impact, for papers by Lauren E. Haydu
Rankless by CCL
2026